Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Biochem Pharmacol. 2018 Dec 19;160:134–145. doi: 10.1016/j.bcp.2018.12.014

Fig. 1. m6A RNA methylation correlated with doxorubicin resistance in colon cancer cells harboring p53 R273H mutations.

Fig. 1.

A, R273H mutation in p53. Codon 273 of p53 RNA was CAU, rather CGU, in TP53-Dox cells. B, Cell responses to doxorubicin. After pretreatments with siMETTL3 or NPC for 3 days, SW48-Dox (wild-type p53) and TP53-Dox (p53/R273H+) cells were treated with doxorubicin (Dox) combined with these agents for 72 hr. siMETTL3, 100 nM siRNA against human METTL3; siRNA-SC, 100 nM siRNA scrambled control; NPC, 20 nM neplanocin A. *, p<0.001, compared to SW48-Dox cells; ** or #, p<0.001 compared to TP53-Dox cells treated with vehicle or siRNA-SC (not depicted in this graph). C, IC50 values for Dox in cells treated with combinations of NPC, siMETTL3 or PDMP. *, p<0.001, compared to SW48-Dox cells; ** or #, p<0.001 compared to TP53-Dox cells treated with vehicle or siRNA-SC.